Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Siddharth Mehra

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1639-8087; OpenAlex author ID A5064761055. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2020: 1 paper · 2021: 4 papers · 2022: 4 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers

Papers 15

  1. Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic c… Co-author DOI 10.1007/s00262-025-04096-y↗
  2. CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic Pancreatitis. First author DOI 10.1016/j.jcmgh.2025.101606↗
  3. Targeting CREB remodels the immune microenvironment to enhance immunotherapy responses in pancreatic cancer Co-author DOI 10.64898/2025.12.04.691935↗
  4. Tumor Cell-Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-1200↗
  5. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1046↗
  6. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-22-0329↗
  7. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02368-w↗
  8. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overco… Co-author DOI 10.1053/j.gastro.2022.07.076↗
  9. Emerging Role of CREB in Epithelial to Mesenchymal Plasticity of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.925687↗
  10. Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy resp… Co-author DOI 10.7554/elife.78921↗
  11. Hsp70 modulates immune response in pancreatic cancer through dendritic cells. Co-author DOI 10.1080/2162402x.2021.1976952↗
  12. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-19-1043↗
  13. Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0083↗
  14. Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress. Co-author DOI 10.3390/cancers13174434↗
  15. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-19-0741↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nagaraj S. Nagathihalli · 13 shared papers, 2020–2025 · strength 2.13
  2. Nipun B. Merchant · 12 shared papers, 2020–2025 · strength 1.79
  3. Austin R. Dosch · 10 shared papers, 2020–2025 · strength 1.43
  4. Iago De Castro Silva · 9 shared papers, 2021–2025 · strength 1.37
  5. Samara P. Singh · 8 shared papers, 2021–2025 · strength 1.28
  6. Haleh Amirian · 5 shared papers, 2023–2025 · strength 0.91
  7. Supriya Srinivasan · 6 shared papers, 2020–2025 · strength 0.88
  8. Jashodeep Datta · 6 shared papers, 2022–2024 · strength 0.85
  9. Nilesh Deshpande · 5 shared papers, 2021–2025 · strength 0.82
  10. Jashodeep Datta · 4 shared papers, 2021–2025 · strength 0.72
  11. Anna Bianchi · 3 shared papers, 2023–2025 · strength 0.50
  12. Christine Isabelle Rafie · 3 shared papers, 2022–2025 · strength 0.46
  13. Peter J. Hosein · 3 shared papers, 2022 · strength 0.39
  14. Prateek Sharma MD · 3 shared papers, 2021–2022 · strength 0.36
  15. Ifeanyichukwu Chinedu Ogobuiro · 2 shared papers, 2023–2025 · strength 0.34
  16. Michael Nathan VanSaun · 2 shared papers, 2021–2025 · strength 0.32
  17. Brent A. Willobee · 2 shared papers, 2020–2021 · strength 0.23
  18. Tulasigeri M. Totiger · 1 shared paper, 2025 · strength 0.20
  19. Kathleen E. DelGiorno · 1 shared paper, 2025 · strength 0.19
  20. Oliver Gene McDonald · 1 shared paper, 2025 · strength 0.19
  21. Vineet Kumar Gupta · 1 shared paper, 2025 · strength 0.19
  22. Eli Gilboa · 1 shared paper, 2023 · strength 0.16
  23. Jonathan S. England · 1 shared paper, 2022 · strength 0.14
  24. Jason A. Castellanos · 1 shared paper, 2021 · strength 0.12
  25. William L. Hwang · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.